182 results on '"Baum, Marc M."'
Search Results
2. Acute antagonism in three-drug combinations for vaginal HIV prevention in humanized mice
- Author
-
Gallay, Philippe A., Ramirez, Christina M., and Baum, Marc M.
- Published
- 2023
- Full Text
- View/download PDF
3. Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis
- Author
-
Gunawardana, Manjula, Remedios-Chan, Mariana, Sanchez, Debbie, Fanter, Rob, Webster, Simon, Webster, Paul, Moss, John A., Trinh, MyMy, Beliveau, Martin, Ramirez, Christina M., Marzinke, Mark A., Kuo, Joseph, Gallay, Philippe A., and Baum, Marc M.
- Published
- 2023
- Full Text
- View/download PDF
4. Vaccine plus microbicide effective in preventing vaginal SIV transmission in macaques
- Author
-
Rahman, Mohammad Arif, Bissa, Massimiliano, Silva de Castro, Isabela, Helmold Hait, Sabrina, Stamos, James D., Bhuyan, Farzana, Hunegnaw, Ruth, Sarkis, Sarkis, Gutowska, Anna, Doster, Melvin N., Moles, Ramona, Hoang, Tanya, Miller Jenkins, Lisa M., Appella, Ettore, Venzon, David J., Choo-Wosoba, Hyoyoung, Cardozo, Timothy, Baum, Marc M., Appella, Daniel H., Robert-Guroff, Marjorie, and Franchini, Genoveffa
- Published
- 2023
- Full Text
- View/download PDF
5. Early SARS-CoV-2 dynamics and immune responses in unvaccinated participants of an intensely sampled longitudinal surveillance study
- Author
-
Gunawardana, Manjula, Webster, Simon, Rivera, Sofia, Cortez, John M, Breslin, Jessica, Pinales, Cristian, Buser, Christopher, Ibarrondo, F Javier, Yang, Otto O, Bobardt, Michael, Gallay, Philippe A, Adler, Amy P, Ramirez, Christina M, Anton, Peter A, and Baum, Marc M
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Immunology ,Infectious Diseases ,Vaccine Related ,Prevention ,Clinical Research ,Biodefense ,Emerging Infectious Diseases ,2.2 Factors relating to the physical environment ,Aetiology ,Infection ,Inflammatory and immune system ,Good Health and Well Being ,Medical research ,Viral infection - Abstract
BackgroundA comprehensive understanding of the SARS-CoV-2 infection dynamics and the ensuing host immune responses is needed to explain the pathogenesis as it relates to viral transmission. Knowledge gaps exist surrounding SARS-CoV-2 in vivo kinetics, particularly in the earliest stages after exposure.MethodsAn ongoing, workplace clinical surveillance study was used to intensely sample a small cohort longitudinally. Nine study participants who developed COVID-19 between November, 2020 and March, 2021 were monitored at high temporal resolution for three months in terms of viral loads as well as associated inflammatory biomarker and antibody responses. CD8 + T cells targeting SARS-CoV-2 in blood samples from study participants were evaluated.ResultsHere we show that the resulting datasets, supported by Bayesian modeling, allowed the underlying kinetic processes to be described, yielding a number of unexpected findings. Early viral replication is rapid (median doubling time, 3.1 h), providing a narrow window between exposure and viral shedding, while the clearance phase is slow and heterogeneous. Host immune responses different widely across participants.ConclusionsResults from our small study give a rare insight into the life-cycle of COVID-19 infection and hold a number of important biological, clinical, and public health implications.
- Published
- 2022
6. Longitudinal COVID-19 Surveillance and Characterization in the Workplace with Public Health and Diagnostic Endpoints
- Author
-
Gunawardana, Manjula, Breslin, Jessica, Cortez, John M, Rivera, Sofia, Webster, Simon, Ibarrondo, F Javier, Yang, Otto O, Pyles, Richard B, Ramirez, Christina M, Adler, Amy P, Anton, Peter A, and Baum, Marc M
- Subjects
Vaccine Related ,Genetics ,Biodefense ,Infectious Diseases ,Prevention ,Lung ,Pneumonia ,Pneumonia & Influenza ,Clinical Research ,Immunization ,Emerging Infectious Diseases ,Infection ,Good Health and Well Being ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,COVID-19 ,Child ,Female ,Humans ,Longitudinal Studies ,Male ,Middle Aged ,Pandemics ,Public Health ,RNA ,Viral ,SARS-CoV-2 ,Workplace ,Young Adult ,antibodies ,asymptomatic ,long-term infection ,serology ,surveillance ,workplace ,Immunology ,Microbiology - Abstract
Public health practices and high vaccination rates currently represent the primary interventions for managing the spread of coronavirus disease 2019 (COVID-19). We initiated a clinical study based on frequent, longitudinal workplace disease surveillance to control severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission among employees and their household members. We hypothesized that the study would reduce the economic burden and loss of productivity of both individuals and small businesses resulting from standard isolation methods, while providing new insights into virus-host dynamics. Study participants (27 employees and 27 household members) consented to provide frequent nasal or oral swab samples that were analyzed by reverse transcription-quantitative PCR (RT-qPCR) for SARS-CoV-2 RNA. Two study participants were found to be infected by SARS-CoV-2 during the study. One subject, a household member, was SARS-CoV-2 RNA positive for at least 71 days and had quantifiable serum virus-specific antibody concentrations for over 1 year. One unrelated employee became positive for SARS-CoV-2 RNA over the course of the study but remained asymptomatic, with low associated viral RNA copy numbers, no detectable serum IgM and IgG concentrations, and IgA concentrations that decayed rapidly (half-life: 1.3 days). A COVID-19 infection model was used to predict that without surveillance intervention, up to 7 employees (95% confidence interval [CI] = 3 to 10) would have become infected, with at most 1 of them requiring hospitalization. Our scalable and transferable surveillance plan met its primary objectives and represents a powerful example of an innovative public health initiative dovetailed with scientific discovery. IMPORTANCE The rapid spread of SARS-CoV-2 and the associated COVID-19 has precipitated a global pandemic heavily challenging our social behavior, economy, and health care infrastructure. In the absence of widespread, worldwide access to safe and effective vaccines and therapeutics, public health measures represent a key intervention for curbing the devastating impacts from the pandemic. We are conducting an ongoing clinical study based on frequent, longitudinal workplace disease surveillance to control SARS-CoV-2 transmission among employees and their household members. Our study was successful in surveying the viral and immune response dynamics in two participants with unusual infections: one remained positive for SARS-CoV-2 for 71 days, while the other was asymptomatic, with low associated viral RNA copy numbers. A COVID-19 infection model was used to predict that without surveillance intervention, up to 7 employees would have become infected, with at most 1 of them requiring hospitalization, underscoring the importance of our program.
- Published
- 2021
7. Publisher Correction: Vaccine plus microbicide effective in preventing vaginal SIV transmission in macaques
- Author
-
Rahman, Mohammad Arif, Bissa, Massimiliano, Silva de Castro, Isabela, Helmold Hait, Sabrina, Stamos, James D., Bhuyan, Farzana, Hunegnaw, Ruth, Sarkis, Sarkis, Gutowska, Anna, Doster, Melvin N., Moles, Ramona, Hoang, Tanya, Miller Jenkins, Lisa M., Appella, Ettore, Venzon, David J., Choo-Wosoba, Hyoyoung, Cardozo, Timothy, Baum, Marc M., Appella, Daniel H., Robert-Guroff, Marjorie, and Franchini, Genoveffa
- Published
- 2023
- Full Text
- View/download PDF
8. Prebiotic reactions in a Mars analog iron mineral system: Effects of nitrate, nitrite, and ammonia on amino acid formation
- Author
-
Barge, Laura M., Flores, Erika, Weber, Jessica M., Fraeman, Abigail A., Yung, Yuk L., VanderVelde, David, Martinez, Eduardo, Castonguay, Amalia, Billings, Keith, and Baum, Marc M.
- Published
- 2022
- Full Text
- View/download PDF
9. Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis
- Author
-
Gunawardana, Manjula, Remedios-Chan, Mariana, Sanchez, Debbie, Webster, Simon, Castonguay, Amalia E., Webster, Paul, Buser, Christopher, Moss, John A., Trinh, MyMy, Beliveau, Martin, Hendrix, Craig W., Marzinke, Mark A., Tuck, Michael, Caprioli, Richard M., Reyzer, Michelle L., Kuo, Joseph, Gallay, Philippe A., and Baum, Marc M.
- Published
- 2022
- Full Text
- View/download PDF
10. A Polymer-Based Extended Release System for Stable, Long-term Intracochlear Drug Delivery
- Author
-
Pierstorff, Erik, Chen, Shanshan, Chaparro, Maria Paola, Cortez, John M, Chen, Yen-Jung, Ryu, Su Young, Tsai, Sherry M, Baum, Marc M, Yang, Wan Wan, Kalinec, Federico, Smith, Thomas, Ludwig, Stacey, and Slattery, William H
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,Biotechnology ,Prevention ,Rehabilitation ,Assistive Technology ,Bioengineering ,Animals ,Anti-Inflammatory Agents ,Cochlea ,Delayed-Action Preparations ,Drug Delivery Systems ,Fluticasone ,Guinea Pigs ,Hearing ,Perilymph ,Pilot Projects ,Polymers ,Corticosteroids ,Drug delivery ,Guinea pig ,Inner ear disorders ,Polymer ,Zoology ,Public Health and Health Services ,Otorhinolaryngology ,Clinical sciences ,Allied health and rehabilitation science - Abstract
ObjectiveInvestigate a new polymer-based drug coating suitability for safe intracochlear delivery and ability to maintain long-term physiologically active levels of the corticosteroid fluticasone propionate.Study designIn vitro dissolution study to evaluate release profiles of polymer-coated drug particles and in vivo studies using a guinea pig model to measure perilymph drug concentrations at specific time points after implantation with polymer-coated drug particles and evaluate their effect on hearing function.MethodsPolymer-coated fluticasone propionate (FP) particles were surgically implanted in guinea pigs through the round window membrane into the cochlear scala tympani. In the pilot study, pre- and post-op hearing thresholds were conducted on days 7, 14, and 42. In a second study, post-op hearing thresholds were conducted on days 90, 120, and 180. Perilymph drug concentrations were measured on the same time points.ResultsIn 15 of 16 animals from day 7 through day 90, drug levels were within the targeted range, with no initial burst release detected. Drug was present in all animals on day 90 and was detected in some animals at 120 and 180 days. Hearing was tested and compared with non-implanted ears. Very good hearing preservation was observed in ears implanted with intracochlear particles when compared with contralateral ears.ConclusionsThe polymer-based extended release system is effective in providing long-term, stable drug delivery for at least 90 days with good hearing outcomes. The results of this study support the potential for achieving long-term drug delivery with a single intracochlear administration.
- Published
- 2018
11. Dicarboxylic acid emissions from a GDI engine equipped with a catalytic gasoline particulate filter
- Author
-
Bock, Noah R.H., Baum, Marc M., Moss, John A., Castonguay, Amalia E., Jocic, Simonne, and Northrop, William F.
- Published
- 2020
- Full Text
- View/download PDF
12. Redox and pH gradients drive amino acid synthesis in iron oxyhydroxide mineral systems
- Author
-
Barge, Laura M., Flores, Erika, Baum, Marc M., VanderVelde, David G., and Russell, Michael J.
- Published
- 2019
13. Comparison of the vaginal microbial communities in women with recurrent genital HSV receiving acyclovir intravaginal rings.
- Author
-
Ursell, Luke K, Gunawardana, Manjula, Chang, Simon, Mullen, Madeline, Moss, John A, Herold, Betsy C, Keller, Marla J, McDonald, Daniel, González, Antonio, Knight, Rob, and Baum, Marc M
- Subjects
Vagina ,Humans ,Bacteria ,Herpes Genitalis ,Recurrence ,Acyclovir ,DNA ,Bacterial ,DNA ,Ribosomal ,RNA ,Ribosomal ,16S ,Administration ,Intravaginal ,Longitudinal Studies ,Sequence Analysis ,DNA ,Contraceptive Devices ,Female ,Female ,Biota ,16S rRNA gene sequencing ,Anti-HSV-2 ,Biofilm ,Intravaginal ring ,Microbicide safety ,Vaginal microbiota ,Clinical Research ,Topical Microbicides ,Infectious Diseases ,Prevention ,Sexually Transmitted Infections ,Infection ,Microbiology ,Medical Microbiology ,Pharmacology and Pharmaceutical Sciences ,Virology - Abstract
Vaginally administered antiviral agents may reduce the risk of HIV and HSV acquisition. Delivery of these drugs using intravaginal rings (IVRs) holds the potential benefits of improving adherence and decreasing systemic exposure, while maintaining steady-state drug levels in the vaginal tract. Elucidating how IVRs interact with the vaginal microbiome constitutes a critical step in evaluating the safety of these devices, as shifts the vaginal microbiome have been linked with several disease states. To date, clinical IVR trials have relied on culture-dependent methods that omit the high diversity of unculturable microbial population. Longitudinal, culture-independent characterization of the microbiota in vaginal samples from 6 women with recurrent genital HSV who used an acyclovir IVR was carried out and compared to the communities developing in biofilms on the IVR surface. The analysis utilized Illumina MiSeq sequence datasets generated from bar-coded amplicons of 16S rRNA gene fragments. Specific taxa in the vaginal communities of the study participants were found to be associated with the duration of recurrent genital HSV status and the number of HSV outbreaks. Taxonomic comparison of the vaginal and IVR biofilm communities did not reveal any significant differences, suggesting that the IVRs were not systematically enriched with members of the vaginal microbiome. Device usage did not alter the participants' vaginal microbial communities, within the confines of the current study design. Rigorous, molecular analysis of the effects of intravaginal devices on the corresponding microbial communities shows promise for integration with traditional approaches in the clinical evaluation of candidate products.
- Published
- 2014
14. Vaginal ecosystem modeling of growth patterns of anaerobic bacteria in microaerophilic conditions
- Author
-
Medina-Colorado, Audrie A., Vincent, Kathleen L., Miller, Aaron L., Maxwell, Carrie A., Dawson, Lauren N., Olive, Trevelyn, Kozlova, Elena V., Baum, Marc M., and Pyles, Richard B.
- Published
- 2017
- Full Text
- View/download PDF
15. Highly synergistic drug combination prevents vaginal HIV infection in humanized mice
- Author
-
Baum, Marc M., Ramirez, Christina M., Moss, John A., Gunawardana, Manjula, Bobardt, Michael, and Gallay, Philippe A.
- Published
- 2020
- Full Text
- View/download PDF
16. Genital epithelial barrier function is conserved by intravaginal rings releasing etonogestrel and ethinyl estradiol.
- Author
-
Liu, Mohan, Vicetti Miguel, Rodolfo D., Quispe Calla, Nirk E., Aceves, Kristen M., Fritts, Linda, Miller, Christopher J., Moss, John A., Baum, Marc M., and Cherpes, Thomas L.
- Abstract
The injectable progestin depot-medroxyprogesterone acetate (DMPA) is a popular contraceptive choice in sub-Saharan Africa although mouse models indicate it weakens genital epithelial integrity and barrier function and increases susceptibility to genital infection. The intravaginal ring NuvaRing® is another contraceptive option that like DMPA suppresses hypothalamic pituitary ovarian (HPO) axis function with local release of progestin (etonogestrel) and estrogen (ethinyl estradiol). As we previously reported that treating mice with DMPA and estrogen averts the loss of genital epithelial integrity and barrier function induced by DMPA alone, in the current investigation we compared genital levels of the cell-cell adhesion molecule desmoglein-1 (DSG1) and genital epithelial permeability in rhesus macaques (RM) treated with DMPA or a NuvaRing®re-sized for RM (N-IVR). While these studies demonstrated comparable inhibition of the HPO axis with DMPA or N-IVR, DMPA induced significantly lower genital DSG1 levels and greater tissue permeability to intravaginally administered low molecular mass molecules. By identifying greater compromise of genital epithelial integrity and barrier function in RM administered DMPA vs. N-IVR, our results add to the growing body of evidence that indicate DMPA weakens a fundamental mechanism of anti-pathogen host defense in the female genital tract. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Accurate measurement of female genital tract fluid dilution in cervicovaginal lavage samples
- Author
-
Churchman, Scott A., Moss, John A., and Baum, Marc M.
- Published
- 2016
- Full Text
- View/download PDF
18. Euphorbia plant latex is inhabited by diverse microbial communities
- Author
-
Gunawardana, Manjula, Hyde, Embriette R., Lahmeyer, Sean, Dorsey, Brian L., La Val, Taylor P., Mullen, Madeline, Yoo, Jennifer, Knight, Rob, and Baum, Marc M.
- Published
- 2015
19. An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate
- Author
-
Baum, Marc M., Butkyavichene, Irina, Churchman, Scott A., Lopez, Gilbert, Miller, Christine S., Smith, Thomas J., and Moss, John A.
- Published
- 2015
- Full Text
- View/download PDF
20. Pharmacokinetic and pharmacodynamic studies of an altrenogest diffusing intravaginal ring for estrus suppression in the mare
- Author
-
Hatzel, Jennifer N, Lederman, Jessica D, Baum, Marc M, and Moss, John A
- Published
- 2023
- Full Text
- View/download PDF
21. An Intravaginal Ring for the Sustained Delivery of Antibodies
- Author
-
Gunawardana, Manjula, Baum, Marc M., Smith, Thomas J., and Moss, John A.
- Published
- 2014
- Full Text
- View/download PDF
22. Comparison of the vaginal microbial communities in women with recurrent genital HSV receiving acyclovir intravaginal rings
- Author
-
Ursell, Luke K., Gunawardana, Manjula, Chang, Simon, Mullen, Madeline, Moss, John A., Herold, Betsy C., Keller, Marla J., McDonald, Daniel, González, Antonio, Knight, Rob, and Baum, Marc M.
- Published
- 2014
- Full Text
- View/download PDF
23. Accessible Research Experiences: A New Paradigm for In-Lab Chemical Education
- Author
-
Baum, Marc M., Krider, Elizabeth S., and Moss, John A.
- Abstract
The preliminary efforts to engage students in the physical sciences through research projects in environmental chemistry are described. The successful involvement of two demographics, community college (CC) students and female students in cutting-edge chemistry research suggests that recruiting methods were effective and the feedback from participants suggests that the chemistry projects selected by the students positively affected their career planning.
- Published
- 2006
24. An Intravaginal Ring for the Simultaneous Delivery of Multiple Drugs
- Author
-
Baum, Marc M., Butkyavichene, Irina, Gilman, Joshua, Kennedy, Sean, Kopin, Etana, Malone, Amanda M., Nguyen, Cali, Smith, Thomas J., Friend, David R., Clark, Meredith R., and Moss, John A.
- Published
- 2012
- Full Text
- View/download PDF
25. Long-Acting Treatments for Hepatitis B.
- Author
-
Thomas, David L, Kiser, Jennifer J, and Baum, Marc M
- Subjects
HEPATITIS B ,DRUG delivery systems ,INJECTIONS ,ANTIRETROVIRAL agents ,CONTROLLED release drugs ,HIGHLY active antiretroviral therapy ,MEDICAL research - Abstract
There are an estimated 257 million persons living with chronic hepatitis B for whom there are multiple potential applications of long-acting antiviral compounds. Current efforts include both injection and implant approaches to formulating derivates of existing anti-HBV compounds such as tenofovir or entecavir. Substantial progress has already occurred especially as aligned with the development of long-acting tenofovir-based medications with dual activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Nonetheless, substantial challenges will need to be overcome before these agents are available. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial
- Author
-
Vincent, Kathleen L., Moss, John A., Marzinke, Mark A., Hendrix, Craig W., Anton, Peter A., Pyles, Richard B., Guthrie, Kate M., Dawson, Lauren, Olive, Trevelyn J., Butkyavichene, Irina, Churchman, Scott A., Cortez, John M., Fanter, Rob, Gunawardana, Manjula, Miller, Christine S., Yang, Flora, Rosen, Rochelle K., Vargas, Sara E., and Baum, Marc M.
- Subjects
United States. Food and Drug Administration -- Powers and duties ,Clinical trials -- Analysis ,Highly active antiretroviral therapy -- Analysis -- Research ,Elastomers -- Product development -- Analysis -- Research ,African Americans -- Analysis -- Health aspects ,Dose-response relationship -- Safety and security measures ,HIV -- Drug therapy ,Antiretroviral agents -- Research -- Health aspects ,Biological sciences - Abstract
Background Intravaginal rings (IVRs) for HIV pre-exposure prophylaxis (PrEP) theoretically overcome some adherence concerns associated with frequent dosing that can occur with oral or vaginal film/gel regimens. An innovative pod-IVR, composed of an elastomer scaffold that can hold up to 10 polymer-coated drug cores (or 'pods'), is distinct from other IVR designs as drug release from each pod can be controlled independently. A pod-IVR has been developed for the delivery of tenofovir (TFV) disoproxil fumarate (TDF) in combination with emtricitabine (FTC), as daily oral TDF-FTC is the only Food and Drug Administration (FDA)-approved regimen for HIV PrEP. A triple combination IVR building on this platform and delivering TDF-FTC along with the antiretroviral (ARV) agent maraviroc (MVC) also is under development. Methodology and findings This pilot Phase I trial conducted between June 23, 2015, and July 15, 2016, evaluated the safety, pharmacokinetics (PKs), and acceptability of pod-IVRs delivering 3 different ARV regimens: 1) TDF only, 2) TDF-FTC, and 3) TDF-FTC-MVC over 7 d. The crossover, open-label portion of the trial (N = 6) consisted of 7 d of continuous TDF pod-IVR use, a wash-out phase, and 7 d of continuous TDF-FTC pod-IVR use. After a 3-mo pause to evaluate safety and PK of the TDF and TDF-FTC pod-IVRs, TDF-FTC-MVC pod-IVRs (N = 6) were evaluated over 7 d of continuous use. Safety was assessed by adverse events (AEs), colposcopy, and culture-independent analysis of the vaginal microbiome (VMB). Drug and drug metabolite concentrations in plasma, cervicovaginal fluids (CVFs), cervicovaginal lavages (CVLs), and vaginal tissue (VT) biopsies were determined via liquid chromatographic-tandem mass spectrometry (LC-MS/MS). Perceptibility and acceptability were assessed by surveys and interviews. Median participant age was as follows: TDF/TDF-FTC group, 26 y (range 24-35 y), 2 White, 2 Hispanic, and 2 African American; TDF-FTC-MVC group, 24.5 y (range 21-41 y), 3 White, 1 Hispanic, and 2 African American. Reported acceptability was high for all 3 products, and pod-IVR use was confirmed by residual drug levels in used IVRs. There were no serious adverse events (SAEs) during the study. There were 26 AEs reported during TDF/TDF-FTC IVR use (itching, discharge, discomfort), with no differences between TDF alone or in combination with FTC observed. In the TDF-FTC-MVC IVR group, there were 12 AEs (itching, discharge, discomfort) during IVR use regardless of attribution to study product. No epithelial disruption/thinning was seen by colposcopy, and no systematic VMB shifts were observed. Median (IQR) tenofovir diphosphate (TFV-DP) tissue concentrations of 303 (277-938) fmol/10.sup.6 cells (TDF), 289 (110-603) fmol/10.sup.6 cells (TDF-FTC), and 302 (177.1-823.8) fmol/10.sup.6 cells (TDF-FTC-MVC) were sustained for 7 d, exceeding theoretical target concentrations for vaginal HIV prevention. The study's main limitations include the small sample size, short duration (7 d versus 28 d), and the lack of FTC triphosphate measurements in VT biopsies. Conclusions An innovative pod-IVR delivery device with 3 different formulations delivering different regimens of ARV drugs vaginally appeared to be safe and acceptable and provided drug concentrations in CVFs and tissues exceeding concentrations achieved by highly protective oral dosing, suggesting that efficacy for vaginal HIV PrEP is achievable. These results show that an alternate, more adherence-independent, longer-acting prevention device based on the only FDA-approved PrEP combination regimen can be advanced to safety and efficacy testing. Trial registration ClinicalTrials.gov NCT02431273, Author(s): Kathleen L. Vincent 1,*, John A. Moss 2, Mark A. Marzinke 3,4, Craig W. Hendrix 3, Peter A. Anton 2,5, Richard B. Pyles 6,7, Kate M. Guthrie 8,9, Lauren [...]
- Published
- 2018
- Full Text
- View/download PDF
27. Biofilm-specific extracellular matrix proteins of nontypeable Haemophilus influenzae
- Author
-
Wu, Siva, Baum, Marc M., Kerwin, James, Guerrero, Debbie, Webster, Simon, Schaudinn, Christoph, VanderVelde, David, and Webster, Paul
- Published
- 2014
- Full Text
- View/download PDF
28. Catalytic effect of Fe/C powder on the formation of gas-phase products of vacuum pyrolysis of N,N′- ethylenebisstearamide
- Author
-
Poskrebyshev, Gregory A., Baum, Marc M., Moss, John A., and Apelian, Diran
- Published
- 2007
- Full Text
- View/download PDF
29. Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings
- Author
-
Moss, John A., Baum, Marc M., Malone, Amanda M., Kennedy, Sean, Kopin, Etana, Nguyen, Cali, Gilman, Josh, Butkyavichene, Irina, Willis, Robyn A., Vincent, Kathleen L., Motamedi, Massoud, and Smith, Thomas J.
- Published
- 2012
- Full Text
- View/download PDF
30. Microbial biofilms on the surface of intravaginal rings worn in non-human primates
- Author
-
Gunawardana, Manjula, Moss, John A., Smith, Thomas J., Kennedy, Sean, Kopin, Etana, Nguyen, Cali, Malone, Amanda M., Rabe, Lorna, Schaudinn, Christoph, Webster, Paul, Srinivasan, Priya, Sweeney, Elizabeth D., Smith, James M., and Baum, Marc M.
- Published
- 2011
- Full Text
- View/download PDF
31. Multicomponent remote sensing of vehicle exhaust by dispersive absorption spectroscopy. 1. Effect of fuel type and catalyst performance
- Author
-
Baum, Marc M., Kiyomiya, Eileen S., Kumar, Sasi, Lappas, Anastasios M., and Lord, Harry C. III
- Subjects
Air Instruments Measurements Inc. -- Research ,Fuel industry -- Research ,Gasoline -- Health aspects ,Gasoline industry -- Research ,Methanol -- Health aspects ,Alcohol industry -- Research ,Environmental issues ,Science and technology ,Oak Crest Institute of Science -- Research - Abstract
Researchers from Air Instruments & Measurements Inc. and the Oak Crest Institute of Science used a remote sensor utilizing ultraviolet and infrared spectrometers to measure over 20 pollutants in the exhaust of 19 in-use vehicles fueled by reformulated gasoline diesel, compressed natural gas, and methanol with 15% gasoline. Results reveal that gasoline and methanol engines contain high levels of NH3.
- Published
- 2000
32. Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting.
- Author
-
Romano, Joseph W., Baum, Marc M., Demkovich, Zach R., Diana, Frank, Dobard, Charles, Feldman, Paul L., Garcia-Lerma, J. Gerardo, Grattoni, Alessandro, Gunawardana, Manjula, Ho, Duy-Khiet, Hope, Thomas J., Massud, Ivana, Milad, Mark, Moss, John A., Pons-Faudoa, Fernanda P., Roller, Shane, van der Straten, Ariane, Srinivasan, Selvi, Veazey, Ronald S., and Zane, Doris
- Abstract
The ability to successfully develop a safe and effective vaccine for the prevention of HIV infection has proven challenging. Consequently, alternative approaches to HIV infection prevention have been pursued, and there have been a number of successes with differing levels of efficacy. At present, only two oral preexposure prophylaxis (PrEP) products are available, Truvada and Descovy. Descovy is a newer product not yet indicated in individuals at risk of HIV-1 infection from receptive vaginal sex, because it still needs to be evaluated in this population. A topical dapivirine vaginal ring is currently under regulatory review, and a long-acting (LA) injectable cabotegravir product shows strong promise. Although demonstrably effective, daily oral PrEP presents adherence challenges for many users, particularly adolescent girls and young women, key target populations. This limitation has triggered development efforts in LA HIV prevention options. This article reviews efforts supported by the Bill & Melinda Gates Foundation, as well as similar work by other groups, to identify and develop optimal LA HIV prevention products. Specifically, this article is a summary review of a meeting convened by the foundation in early 2020 that focused on the development of LA products designed for extended delivery of tenofovir alafenamide (TAF) for HIV prevention. The review broadly serves as technical guidance for preclinical development of LA HIV prevention products. The meeting examined the technical feasibility of multiple delivery technologies, in vivo pharmacokinetics, and safety of subcutaneous (SC) delivery of TAF in animal models. Ultimately, the foundation concluded that there are technologies available for long-term delivery of TAF. However, because of potentially limited efficacy and possible toxicity issues with SC delivery, the foundation will not continue investing in the development of LA, SC delivery of TAF products for HIV prevention. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
33. The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.
- Author
-
Bobardt, Michael, Ramirez, Christina M., Baum, Marc M., Ure, Daren, Foster, Robert, and Gallay, Philippe A.
- Subjects
CYCLOPHILINS ,MICE ,LIVER cells ,CIRRHOSIS of the liver ,RIBAVIRIN - Abstract
We and others previously reported that the direct-acting agents (DAA) NS5A inhibitors (NS5Ai) and the host-targeting agents cyclophilin inhibitors (CypIs) inhibit HCV replication in vitro. In this study, we investigated whether the combination of NS5Ai and CypI offers a potent anti-HCV effect in vivo. A single administration of NS5Ai or CypI alone to HCV-infected humanized-mice inhibits HCV replication. The combination of NS5Ai with CypI suppresses HCV (GT1a, GT2a, GT3a and GT4a) replication in an additive manner. NS5Ai/CypI combinations provide a statistically more profound anti-HCV inhibition for GT2a and GT3a than GT1a and GT4a, leading to a fastest and deepest inhibition of GT2a and GT3a replications. Combining CypI with NS5Ai prevents the viral rebound normally observed in mice treated with NS5Ai alone. Results were confirmed in mice implanted with human hepatocytes from different donors. Therefore, the combination of NS5Ai with CypI may serve as a regimen for the treatment of HCV patients with specific genotypes and disorder conditions, which diminish sustain viral response levels to DAA, such as GT3a infection, cirrhosis, and DAA resistance associated with the selection of resistance-associated substitutions present at baseline or are acquired during treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
34. Characterization of structures in biofilms formed by a Pseudomonas fluorescens isolated from soil
- Author
-
Wu Siva, McDonald Kent, Pandita Ragini, O'Keeffe Teresa, Kainović Aleksandra, Baum Marc M, and Webster Paul
- Subjects
Microbiology ,QR1-502 - Abstract
Abstract Background Microbial biofilms represent an incompletely understood, but fundamental mode of bacterial growth. These sessile communities typically consist of stratified, morphologically-distinct layers of extracellular material, where numerous metabolic processes occur simultaneously in close proximity. Limited reports on environmental isolates have revealed highly ordered, three-dimensional organization of the extracellular matrix, which may hold important implications for biofilm physiology in vivo. Results A Pseudomonas spp. isolated from a natural soil environment produced flocculent, nonmucoidal biofilms in vitro with unique structural features. These mature biofilms were made up of numerous viable bacteria, even after extended culture, and contained up to 50% of proteins and accumulated 3% (by dry weight) calcium, suggesting an important role for the divalent metal in biofilm formation. Ultrastructurally, the mature biofilms contained structural motifs consisting of dense, fibrillary clusters, nanofibers, and ordered, honeycomb-like chambers enveloped in thin sheets. Conclusion Mature biofilms contained living bacteria and were structurally, chemically, and physiologically heterogeneous. The principal architectural elements observed by electron microscopy may represent useful morphological clues for identifying bacterial biofilms in vivo. The complexity and reproducibility of the structural motifs observed in bacterial biofilms appear to be the result of organized assembly, suggesting that this environmental isolate may possess ecological advantages in its natural habitat.
- Published
- 2009
- Full Text
- View/download PDF
35. Synthesis and Characterization of Mixed-Valent Iron Layered Double Hydroxides ("Green Rust").
- Author
-
Aguirre, Vincent P., Jocic, Simonne, Webster, Paul, Buser, Christopher, Moss, John A., Barge, Laura M., Tang, Yijie, Guo, Yisong, and Baum, Marc M.
- Published
- 2021
- Full Text
- View/download PDF
36. Concentrative Nucleoside Transporter 3 Is Located on Microvilli of Vaginal Epithelial Cells.
- Author
-
Webster, Paul, Saito, Kaori, Cortez, John, Ramirez, Christina, and Baum, Marc M.
- Published
- 2020
- Full Text
- View/download PDF
37. Accessible research experiences: A new paradigm for in-lab chemical education
- Author
-
Baum, Marc M., Krider, Elizabeth S., and Moss, John A.
- Subjects
Chemical research -- Educational aspects ,Chemistry -- Study and teaching ,Chemistry ,Education ,Science and technology - Abstract
The preliminary efforts to engage students in the physical sciences through research projects in environmental chemistry are described. The successful involvement of two demographics, community college (CC) students and female students in cutting-edge chemistry research suggests that recruiting methods were effective and the feedback from participants suggests that the chemistry projects selected by the students positively affected their career planning.
- Published
- 2006
38. Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc.
- Author
-
Vincent, Kathleen Listiak, Moss, John A., Marzinke, Mark A., Hendrix, Craig W., Anton, Peter A., Gunawardana, Manjula, Dawson, Lauren N., Olive, Trevelyn J., Pyles, Richard B., and Baum, Marc M.
- Subjects
HIV prevention ,HIV-positive persons ,AIDS treatment ,ANTIRETROVIRAL agents ,ANTI-HIV agents - Abstract
Background: Intravaginal rings (IVRs) can deliver antiretroviral (ARV) agents for HIV pre-exposure prophylaxis (PrEP), theoretically overcoming adherence concerns associated with frequent dosing. However, topical vaginal ARV drug delivery has not simultaneously led to sufficient rectal drug exposure to likely protect from HIV infection as a result of receptive anal intercourse (RAI). Unprotected RAI has a higher risk of infection per sex act and, for women, also can be associated with vaginal exposure during a single sexual encounter, especially in higher-risk subsets of women. The physiologically inflamed, activated, immune-cell dense colorectal mucosa is increasingly appreciated as the sexual compartment with highly significant risk; this risk is increased in the setting of co-infections. Ex vivo studies have shown that colorectal tissue and rectal fluid concentrations correlated with HIV protection. Given these important results, efforts to document colorectal compartment ARV drug concentration from pod-IVR delivery was assessed to determine if vaginal application could provide protective ARV levels in both compartments. Methodology/Principal findings: A crossover clinical trial (N = 6) evaluated 7 d of continuous TDF pod-IVR use, a wash-out phase, followed by 7 d with a TDF-FTC pod-IVR. A subsequent clinical trial (N = 6) consisted of 7 d of continuous TDF-FTC-MVC pod-IVR use. Rectal fluids were collected on Day 7 at IVR removal in all three ARV-exposures (two Phase 1 trials) and drug concentrations quantified by LC-MS/MS. Median rectal fluid concentrations of TFV, the hydrolysis product of the prodrug TDF, were between 0.66 ng mg
-1 (TDF pod-IVR group) and 1.11 ng mg-1 (TDF-FTC pod-IVR group), but below the analytical lower limit of quantitation in 5/6 samples in the TDF-FTC-MVC pod-IVR group. Unexpectedly, median FTC (TDF-FTC pod-IVR, 20.3 ng mg-1 ; TDF-FTC-MVC pod-IVR, 0.18 ng mg-1 ), and MVC rectal fluid concentrations (0.84 ng mg-1 ) were quantifiable and higher than their respective in vitro EC50 values in most samples. Due to participant burden in these exploratory trials, rectal fluid was used as a surrogate for rectal tissue, where drug concentrations are expected to be higher. Conclusions/Significance: The concentrations of FTC and MVC in rectal fluids obtained in two exploratory clinical trials of IVRs delivering ARV combinations exceeded levels associated with in vitro efficacy in HIV inhibition. Unexpectedly, MVC appeared to depress the distribution of TFV and FTC into the rectal lumen. Here we show that vaginal delivery of ARV combinations may provide adherence and coitally independent dual-compartment protection from HIV infection during both vaginal and receptive anal intercourse. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
39. User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: A mixed methods study of acceptability and use experiences.
- Author
-
Guthrie, Kate M., Rosen, Rochelle K., Vargas, Sara E., Getz, Melissa L., Dawson, Lauren, Guillen, Melissa, Ramirez, Jaime J., Baum, Marc M., and Vincent, Kathleen L.
- Subjects
HIV prevention ,VAGINAL rings (Contraceptives) ,DRUG delivery systems ,DRUG efficacy ,PATIENT compliance - Abstract
Background: Effective HIV prevention requires efficient delivery of safe and efficacious drugs and optimization of user adherence. The user’s experiences with the drug, delivery system, and use parameters are critical to product acceptability and adherence. Prevention product developers have the opportunity to directly control a drug delivery system and its impact on acceptability and adherence, as well as product efficacy. Involvement of potential users during preclinical design and development can facilitate this process. We embedded a mixed methods user evaluation study into a safety and pharmacokinetics (PK) trial of a pod-intravaginal ring delivering antiretroviral agents. Methodology: Women enrolled in two cohorts, ultimately evaluating the safety/PK of a pod-IVRs delivering TDF-alone, TDF-FTC, and/or TDF-FTC-MVC. A 7-day use period was targeted for each pod-IVR, regardless of drug or drug combination. During the clinical study, participants provided both quantitative (i.e., survey) and qualitative (i.e., in-depth interview) data capturing acceptability, perceptibility, and adherence behaviors. Initial sexual and reproductive health history surveys, daily diaries, a final acceptability and willingness to use survey, and a qualitative in-depth interview comprised the user evaluation data for each pod-IVR experienced by the participants. Findings: Overall, the majority of participants (N = 10) reported being willing to use the pod-IVR platform for HIV prevention should it advance to market. Confidence to use the pod-IVR (e.g., insertion, removal) was high. There were no differences noted in the user experience of the pod-IVR platform; that is, whether the ring delivered TDF-alone, TDF-FTC, or TDF-FTC-MVC, users’ experiences of the ring were similar and acceptable. Participants did report specific experiences, both sensory and behavioral, that impacted their use behaviors with respect to the ring, and which could ultimately impact acceptability and adherence. These experiences, and user evaluations elicited by them, could both challenge use or be used to leverage use in future trials and product rollout once fully articulated. Conclusions: High willingness-to-use data and lack of salient differences in user experiences related to use of the pod-IVR platform (regardless of agents delivered) suggests that the pod-IVR is a feasible and acceptable drug delivery device in and of itself. This finding holds promise both for an anti-HIV pod-IVR and, potentially, a multipurpose prevention pod-IVR that could deliver both prevention for sexually transmitted infections (STIs) including HIV and contraception. Given the very early clinical trial context, further acceptability, perceptibility, and adherence data should continue to be explored, in the context of longer use periods (e.g., 28-day ring use), and in the contexts of sexual activity and menses. Using early design and development contexts to gain insights into potential challenges and facilitators of drug delivery systems such as the pod-IVR could save valuable resources and time as a potential biomedical technology moves through the clinical trial pipeline and into real-world use. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
40. Dicarboxylic Acid Emissions from Aftertreatment Equipped Diesel Engines.
- Author
-
Bock, Noah, Baum, Marc M., Anderson, Mackenzie B., Pesta, Anai's, and Northrop, William F.
- Subjects
- *
DICARBOXYLIC acids , *EMISSIONS (Air pollution) , *DIESEL motors , *ATMOSPHERIC nucleation , *GAS chromatography/Mass spectrometry (GC-MS) , *PARTICULATE matter - Abstract
Dicarboxylic acids play a key role in atmospheric particle nucleation. Though long assumed to originate from primary sources, little experimental evidence exists directly linking combustion to dieir emissions. Ln this work, we sought definitive proof diat dicarboxylic acids are produced in diesel engines and that they can slip dirough a modern aftertreatment system (ATS) at low exhaust temperatures. One difficulty in measuring dicarboxylic acid emissions is that they cannot be identified using conventional mass spectroscopy tecliniques. In this work, we refined a derivatization gas chromatography -- mass spectroscopy technique to measure 11 mono-and dicarboxylic acids from plain and KOH impregnated quartz filters. Filters were loaded with exhaust from a modern passenger car diesel engine on a dynamometer sampled before and after an ATS consisting of an oxidation catalyst and diesel particulate filter. Our findings confirm that dicarboxylic acids are produced in diesel engine combustion, especially during low temperature combustion modes that emit significant concentrations of partially combusted hydrocarbons. Exhaust acids were largely removed by a fully warmed-up ATS, mitigating their environmental impact. Our results also suggest that dicarboxylic acids do not participate in primary particle formation in dilute engine exhaust as low quantities were collected on unimpregnated filters. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
41. Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model.
- Author
-
Smith, James M., Moss, John A., Srinivasan, Priya, Butkyavichene, Irina, Gunawardana, Manjula, Fanter, Rob, Miller, Christine S., Sanchez, Debbie, Yang, Flora, Ellis, Shanon, Zhang, Jining, Marzinke, Mark A., Hendrix, Craig W., Kapoor, Amita, and Baum, Marc M.
- Subjects
HIV prevention ,VAGINAL contraceptives ,HERPES simplex prevention ,PREGNANT women ,ETHINYL estradiol ,THERAPEUTICS - Abstract
Globally, women bear an uneven burden for sexual HIV acquisition. Results from two clinical trials evaluating intravaginal rings (IVRs) delivering the antiretroviral agent dapivirine have shown that protection from HIV infection can be achieved with this modality, but high adherence is essential. Multipurpose prevention technologies (MPTs) can potentially increase product adherence by offering protection against multiple vaginally transmitted infections and unintended pregnancy. Here we describe a coitally independent, long-acting pod-IVR MPT that could potentially prevent HIV and HSV infection as well as unintended pregnancy. The pharmacokinetics of MPT pod-IVRs delivering tenofovir alafenamide hemifumarate (TAF
2 ) to prevent HIV, acyclovir (ACV) to prevent HSV, and etonogestrel (ENG) in combination with ethinyl estradiol (EE), FDA-approved hormonal contraceptives, were evaluated in pigtailed macaques (N = 6) over 35 days. Pod IVRs were exchanged at 14 days with the only modification being lower ENG release rates in the second IVR. Plasma progesterone was monitored weekly to determine the effect of ENG/EE on menstrual cycle. The mean in vivo release rates (mg d-1 ) for the two formulations over 30 days ranged as follows: TAF2 0.35–0.40; ACV 0.56–0.70; EE 0.03–0.08; ENG (high releasing) 0.63; and ENG (low releasing) 0.05. Mean peak progesterone levels were 4.4 ± 1.8 ng mL-1 prior to IVR insertion and 0.075 ± 0.064 ng mL-1 for 5 weeks after insertion, suggesting that systemic EE/ENG levels were sufficient to suppress menstruation. The TAF2 and ACV release rates and resulting vaginal tissue drug concentrations (medians: TFV, 2.4 ng mg-1 ; ACV, 0.2 ng mg-1 ) may be sufficient to protect against HIV and HSV infection, respectively. This proof of principle study demonstrates that MPT-pod IVRs could serve as a potent biomedical prevention tool to protect women’s sexual and reproductive health and may increase adherence to HIV PrEP even among younger high-risk populations. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
42. Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice.
- Author
-
Gallay, Philippe A., Chatterji, Udayan, Kirchhoff, Aaron, Gandarilla, Angel, Gunawardana, Manjula, Pyles, Richard B., Marzinke, Mark A., Moss, John A., and Baum, Marc M.
- Subjects
HIV infection transmission ,VIRUS disease transmission ,ANTIRETROVIRAL agents ,LABORATORY mice ,BONE marrow ,EMTRICITABINE - Abstract
With more than 7,000 new HIV infections daily worldwide, there is an urgent need for non-vaccine biomedical prevention (nBP) strategies that are safe, effective, and acceptable. Clinical trials have demonstrated that pre-exposure prophylaxis (PrEP) with antiretrovirals (ARVs) can be effective at preventing HIV infection. In contrast, other trials using the same ARVs failed to show consistent efficacy. Topical (vaginal and rectal) dosing is a promising regimen for HIV PrEP as it leads to low systematic drug exposure. A series of titration studies were carried out in bone marrow/liver/thymus (BLT) mice aimed at determining the adequate drug concentrations applied vaginally or rectally that offer protection against rectal or vaginal HIV challenge. The dose-response relationship of these agents was measured and showed that topical tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) can offer 100% protection against rectal or vaginal HIV challenges. From the challenge data, EC
50 values of 4.6 μM for TDF and 0.6 μM for FTC for HIV vaginal administration and 6.1 μM TDF and 0.18 μM for FTC for rectal administration were obtained. These findings suggest that the BLT mouse model is highly suitable for studying the dose-response relationship in single and combination ARV studies of vaginal or rectal HIV exposure. Application of this sensitive HIV infection model to more complex binary and ternary ARV combinations, particularly where agents have different mechanisms of action, should allow selection of optimal ARV combinations to be advanced into pre-clinical and clinical development as nBP products. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
43. An intravaginal ring for real-time evaluation of adherence to therapy.
- Author
-
Moss, John A., Baum, Marc M., Easley, Jeremiah T., Cox, Darren M., and Smith, Thomas J.
- Subjects
- *
LIVESTOCK , *ETIOLOGY of diseases , *PATHOLOGY , *SHEEP , *HIV infections - Abstract
Two recent Phase III clinical trials to investigate an intravaginal ring for preventing HIV infection demonstrated that adherence to prescribed device use was a primary driver of efficacy. Surrogate methods for determining adherence in the studies were limited in their inability to monitor temporal patterns of use and allow deconvolution of the effects of adherence and device efficacy on HIV infection rates. To address this issue, we have developed functionality in an intravaginal ring to continuously monitor when the device is being used and maintain a log of adherence that can be accessed by clinicians after it is removed. An electronic module fabricated with common, inexpensive electronic components was encapsulated in a silicone intravaginal ring. The device uses temperature as a surrogate measure of periods of device insertion and removal, and stores a record of the data for subsequent retrieval. The adherence-monitoring intravaginal ring accurately recorded the device status over 33 simulated IN-OUT cycles and more than 1000 measurement cycles in vitro. Following initial in vitro testing in a temperature-controlled chamber, the device was evaluated in vivo in sheep using a predetermined insertion/removal pattern to simulate intravaginal ring use. After insertion into the vaginal cavity of a sheep, the logged data correctly indicated the device status over 29 hours of continuous measurement including three cycles of insertion and removal. The device described here is a promising, low-cost method for real-time adherence assessment in clinical trials involving medicated intravaginal rings or other intravaginal devices. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
44. Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV Exposures.
- Author
-
Srinivasan, Priya, Moss, John A., Gunawardana, Manjula, Churchman, Scott A., Yang, Flora, Dinh, Chuong T., Mitchell, James M., Zhang, Jining, Fanter, Rob, Miller, Christine S., Butkyavichene, Irina, McNicholl, Janet M., Smith, Thomas J., Baum, Marc M., and Smith, James M.
- Subjects
HIV infections ,THERAPEUTICS ,EMTRICITABINE-tenofovir ,PATIENT compliance ,DRUG delivery systems ,CLINICAL trials ,LABORATORY monkeys - Abstract
Topical preexposure prophylaxis (PrEP) against HIV has been marginally successful in recent clinical trials with low adherence rates being a primary factor for failure. Controlled, sustained release of antiretroviral (ARV) drugs may help overcome these low adherence rates if the product is protective for extended periods of time. The oral combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) is currently the only FDA-approved ARV drug for HIV PrEP. A novel pod-intravaginal ring (IVR) delivering TDF and FTC at independently controlled rates was evaluated for efficacy at preventing SHIV162p3 infection in a rigorous, repeat low-dose vaginal exposure model using normally cycling female pigtailed macaques. Six macaques received pod-IVRs containing TDF (65 mg) and FTC (68 mg) every two weeks, and weekly vaginal exposures to 50 TCID
50 of SHIV162p3 began one week after the first pod-IVR insertion. All pod-IVR-treated macaques were fully protected throughout the study (P = 0.0002, Log-rank test), whereas all control animals became infected with a median of 4 exposures to infection. The topical, sustained release of TDF and FTC from the pod-IVR maintained protective drug levels in macaques over four months of virus exposures. This novel and versatile delivery system has the capacity to deliver and maintain protective levels of multiple drugs and the protection observed here warrants clinical evaluation of this pod-IVR design. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
45. Beta- Lactam Antibiotics Stimulate Biofilm Formation in Non-Typeable Haemophilus influenzae by Up-Regulating Carbohydrate Metabolism.
- Author
-
Wu, Siva, Li, Xiaojin, Gunawardana, Manjula, Maguire, Kathleen, Guerrero-Given, Debbie, Schaudinn, Christoph, Wang, Charles, Baum, Marc M., and Webster, Paul
- Subjects
BETA-lactamase inhibitors ,HAEMOPHILUS influenzae ,CARBOHYDRATE metabolism ,PHYSIOLOGICAL effects of antibiotics ,MEDICAL care costs ,BIOFILMS ,THERAPEUTICS - Abstract
Non-typeable Haemophilus influenzae (NTHi) is a common acute otitis media pathogen, with an incidence that is increased by previous antibiotic treatment. NTHi is also an emerging causative agent of other chronic infections in humans, some linked to morbidity, and all of which impose substantial treatment costs. In this study we explore the possibility that antibiotic exposure may stimulate biofilm formation by NTHi bacteria. We discovered that sub-inhibitory concentrations of beta-lactam antibiotic (i.e., amounts that partially inhibit bacterial growth) stimulated the biofilm-forming ability of NTHi strains, an effect that was strain and antibiotic dependent. When exposed to sub-inhibitory concentrations of beta-lactam antibiotics NTHi strains produced tightly packed biofilms with decreased numbers of culturable bacteria but increased biomass. The ratio of protein per unit weight of biofilm decreased as a result of antibiotic exposure. Antibiotic-stimulated biofilms had altered ultrastructure, and genes involved in glycogen production and transporter function were up regulated in response to antibiotic exposure. Down-regulated genes were linked to multiple metabolic processes but not those involved in stress response. Antibiotic-stimulated biofilm bacteria were more resistant to a lethal dose (10 µg/mL) of cefuroxime. Our results suggest that beta-lactam antibiotic exposure may act as a signaling molecule that promotes transformation into the biofilm phenotype. Loss of viable bacteria, increase in biofilm biomass and decreased protein production coupled with a concomitant up-regulation of genes involved with glycogen production might result in a biofilm of sessile, metabolically inactive bacteria sustained by stored glycogen. These biofilms may protect surviving bacteria from subsequent antibiotic challenges, and act as a reservoir of viable bacteria once antibiotic exposure has ended. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
46. Cultivated Vaginal Microbiomes Alter HIV-1 Infection and Antiretroviral Efficacy in Colonized Epithelial Multilayer Cultures.
- Author
-
Pyles, Richard B., Vincent, Kathleen L., Baum, Marc M., Elsom, Barry, Miller, Aaron L., Maxwell, Carrie, Eaves-Pyles, Tonyia D., Li, Guangyu, Popov, Vsevolod L., Nusbaum, Rebecca J., and Ferguson, Monique R.
- Subjects
HIV infections ,VAGINAL diseases ,ANTIRETROVIRAL agents ,DRUG efficacy ,EPITHELIAL cell culture ,MUCOUS membranes ,SEXUALLY transmitted diseases - Abstract
There is a pressing need for modeling of the symbiotic and at times dysbiotic relationship established between bacterial microbiomes and human mucosal surfaces. In particular clinical studies have indicated that the complex vaginal microbiome (VMB) contributes to the protection against sexually-transmitted pathogens including the life-threatening human immunodeficiency virus (HIV-1). The human microbiome project has substantially increased our understanding of the complex bacterial communities in the vagina however, as is the case for most microbiomes, very few of the community member species have been successfully cultivated in the laboratory limiting the types of studies that can be completed. A genetically controlled ex vivo model system is critically needed to study the complex interactions and associated molecular dialog. We present the first vaginal mucosal culture model that supports colonization by both healthy and dysbiotic VMB from vaginal swabs collected from routine gynecological patients. The immortalized vaginal epithelial cells used in the model and VMB cryopreservation methods provide the opportunity to reproducibly create replicates for lab-based evaluations of this important mucosal/bacterial community interface. The culture system also contains HIV-1 susceptible cells allowing us to study the impact of representative microbiomes on replication. Our results show that our culture system supports stable and reproducible colonization by VMB representing distinct community state types and that the selected representatives have significantly different effects on the replication of HIV-1. Further, we show the utility of the system to predict unwanted alterations in efficacy or bacterial community profiles following topical application of a front line antiretroviral. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
47. The Fuel Cell Model of Abiogenesis: A New Approach to Origin-of-Life Simulations.
- Author
-
Barge, Laura M., Kee, Terence P., Doloboff, Ivria J., Hampton, Joshua M.P., Ismail, Mohammed, Pourkashanian, Mohamed, Zeytounian, John, Baum, Marc M., Moss, John A., Lin, Chung-Kuang, Kidd, Richard D., and Kanik, Isik
- Published
- 2014
- Full Text
- View/download PDF
48. Integrated Method for the Measurement of Trace Atmospheric Bases.
- Author
-
Key, Daryl, Stihle, Jerome, Petit, Jean-Eudes, Bonnet, Cécile, Depernon, Lauriane, Liu, Oscar, Kennedy, Sean, Latimer, Robyn, Burgoyne, Marnie, Wanger, Darcy, Webster, Alexandre, Casunuran, Samantha, Hidalgo, Sergio, Thomas, Mark, Moss, John A., and Baum, Marc M.
- Subjects
HIGH performance liquid chromatography ,GAS chromatography ,TRACE analysis ,MASS spectrometry ,BASES (Chemistry) ,ATMOSPHERIC chemistry - Abstract
The article presents a study which analyzes the potential of integrated method for the measurement of trace atmospheric bases. The project uses a chromatography instrumentation which consists a high performance liquid chromatography with mass spectrometric detection and a gas chromatography. An overview of the preparation of authentic samples is provided. The conducted Denuder and Impinger efficiency tests were highlighted.
- Published
- 2011
49. Characterization of structures in biofilms formed by a Pseudomonas fluorescens isolated from soil.
- Author
-
Baum, Marc M., Kainovic, Aleksandra, O'Keeffe, Teresa, Pandita, Ragini, McDonald, Kent, Wu, Siva, and Webster, Paul
- Subjects
- *
BIOFILMS , *PSEUDOMONAS fluorescens , *SOIL microbiology , *MICROBIAL growth , *MICROBIAL aggregation - Abstract
Background: Microbial biofilms represent an incompletely understood, but fundamental mode of bacterial growth. These sessile communities typically consist of stratified, morphologically-distinct layers of extracellular material, where numerous metabolic processes occur simultaneously in close proximity. Limited reports on environmental isolates have revealed highly ordered, three-dimensional organization of the extracellular matrix, which may hold important implications for biofilm physiology in vivo. Results: A Pseudomonas spp. isolated from a natural soil environment produced flocculent, nonmucoidal biofilms in vitro with unique structural features. These mature biofilms were made up of numerous viable bacteria, even after extended culture, and contained up to 50% of proteins and accumulated 3% (by dry weight) calcium, suggesting an important role for the divalent metal in biofilm formation. Ultrastructurally, the mature biofilms contained structural motifs consisting of dense, fibrillary clusters, nanofibers, and ordered, honeycomb-like chambers enveloped in thin sheets. Conclusion: Mature biofilms contained living bacteria and were structurally, chemically, and physiologically heterogeneous. The principal architectural elements observed by electron microscopy may represent useful morphological clues for identifying bacterial biofilms in vivo. The complexity and reproducibility of the structural motifs observed in bacterial biofilms appear to be the result of organized assembly, suggesting that this environmental isolate may possess ecological advantages in its natural habitat. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
50. Hydrogen Cyanide Exhaust Emissions from In-Use Motor Vehicles.
- Author
-
Baum, Marc M., Moss, John A., Pastel, Stephen H., and Poskrebyshev, Gregory A.
- Subjects
- *
CYANIDES , *MOTOR vehicles , *EMISSIONS (Air pollution) , *AIR pollution , *CARBON monoxide , *POISONOUS gases , *NITRIC oxide , *NITROGEN compounds - Abstract
Motor vehicle exhaust emissions are known to contain hydrogen cyanide (HCN), but emission rate data are scarce and, in the case of idling vehicles, date back over 20 years. For the first time, vehicular HCN exhaust emissions from a modern, in-use fleet at idle have been measured. The 14 tested light duty motor vehicles were operating at idle as these conditions are associated with the highest risk exposure scenarios (i.e., enclosed spaces). Vehicular HCN was detected in 89% of the sampled exhaust streams and did not correlate with instantaneous air-fuel-ratio or with any single, coemitted pollutant. However, a moderate correlation between HCN emissions and the product of carbon monoxide and nitric oxide emissions was observed under cold-start conditions. Fleet average, cold-start, undiluted HCN emissions were 105 ± 97 ppbV (maximum: 278 ppbV), whereas corresponding emissions from vehicles operating under stabilized conditions were 79 ± 71 ppbV (maximum: 245 ppbV); mean idle fleet HCN emission rates were 39 ± 35 and 21 ± 18 μg-min-1 for cold-start and stabilized vehicles, respectively. The significance of these results is discussed in terms of HCN emissions inventories in the South Coast Air Basin of California and of health risks due to exposure to vehicular HCN. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.